Sign up here for GlobalData's free bi-weekly Covid-19 report on the latest information your industry needs to know.
Accelerated Enrollment Solutions (AES) has launched new patient-transfer programme to assist biopharmaceutical companies amid the coronavirus (Covid-19) pandemic.
The programme will assist the companies with transfering clinical trial patients to AES’ dedicated research sites from other research facilities affected by the coronavirus crisis. It will also help them maintain business continuity.
Due to the ongoing pandemic crisis, academic and hospital-based sites have turned their attention to the front-line care of Covid-19 patients.
Biopharmaceutical companies are delaying or cancelling clinical trials of potential new medicines and ending patient participation as independent sites experience low operating capacity related to concerns over Covid-19.
The company noted that its patient-transfer programme is designed to address this issue through its global site organisation, which includes dedicated research sites committed exclusively to clinical research.
AES general manager Roger Smith said: “The transfer of patients to AES physical and virtual sites supports ongoing patient participation and allows for the continued collection of data for important trials supporting potentially life-changing therapies that aren’t necessarily connected to Covid-19.
“As staff members from other sites are being called to support Covid-19 endeavours, this is a way for us to help their trial patients and support clinical research continuity, in addition to our organisation’s ongoing work with our customers’ Covid-19 research.”
AES has a global footprint with over 180 research locations in 17 countries. The company supports the transfer of patients based on the sites’ proximity to the patients and their ability to support the trial protocol.
These sites are currently operating under the governments’ essential-business provision.
AES is following pandemic-related guidance from the US Food and Drug Administration (FDA) and European Medicines Agency to accommodate the transfer of patients between study sites.